Physician profile
Michael W Grof
NPI 1740238005
$12,704.40
in general payments reported to CMS, 2019-2025
47 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,599 · 2020: $1,244 · 2021: $1,412 · 2022: $1,123 · 2023: $1,269 · 2024: $1,177 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,327.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $5,711.98 | 2019-2025 | Hizentra |
| Pfizer INC. | $562.11 | 2021-2025 | |
| Biogen, INC. | $539.70 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $526.32 | 2019-2025 | Mavenclad |
| Genentech USA, INC. | $468.92 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $423.40 | 2019-2024 | Briviact, Rystiggo |
| Abbvie INC. | $325.80 | 2021-2025 | |
| Allergan, INC. | $294.48 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $289.57 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $282.57 | 2020-2025 | |
| Genzyme Corporation | $254.97 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.09 | 2022-2025 | Hyqvia, Gammagard |
| Novartis Pharmaceuticals Corporation | $217.04 | 2019-2024 | |
| Neurelis, INC. | $215.59 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $187.12 | 2019-2023 | Soliris |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $161.59 | 2019-2021 | |
| Grifols USA, LLC | $150.55 | 2023-2025 | Gamunex-C |
| Acorda Therapeutics, INC | $138.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $135.03 | 2021-2022 | |
| Lilly USA, LLC | $123.97 | 2019-2023 | Emgality |
| Neurocrine Biosciences, INC. | $119.35 | 2022-2024 | Ingrezza, Ongentys |
| Kyowa Kirin, INC. | $112.74 | 2021-2024 | Nourianz |
| Argenx US, INC. | $94.38 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $87.37 | 2024-2025 | |
| Eisai INC. | $86.28 | 2020-2021 | |
| Celgene Corporation | $84.36 | 2022-2025 | Zeposia |
| Hospira, INC. | $81.70 | 2024-2025 | |
| Lundbeck LLC | $77.85 | 2022-2023 | Vyepti |
| Adamas Pharmaceuticals, INC. | $73.50 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $73.25 | 2021-2023 | Acthar |
| Avanir Pharmaceuticals, INC. | $66.50 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $50.99 | 2023-2024 | Aptiom |
| Nevro Corp. | $49.11 | 2022-2023 | Senza |
| Alnylam Pharmaceuticals INC. | $47.06 | 2023-2024 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $46.78 | 2023-2024 | Nuedexta |
| Catalyst Pharmaceuticals, INC. | $42.22 | 2020 | |
| Supernus Pharmaceuticals, INC. | $34.14 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $23.76 | 2019 | |
| Acadia Pharmaceuticals INC | $23.15 | 2023 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $22.81 | 2021 | |
| Upsher-Smith Laboratories LLC | $22.32 | 2020 | |
| Medtronic USA, INC. | $22.07 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.84 | 2022 | |
| Bio Products Laboratory USA, INC. | $20.62 | 2023 | Coagadex, Gammaplex |
| Aucta Pharmaceuticals, INC. | $19.68 | 2024 | Motpoly Xr |
| Kedrion Biopharma, INC. | $19.67 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Merz Pharmaceuticals, LLC | $18.35 | 2025 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Grof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.